News Details
11/04/2025 08:28
Cipla - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Company has received final approval from USFDA for ANDA submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial ('Protein-bound Paclitaxel') on 10th April, 2025